Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Alcohols Stories

2014-04-01 08:30:10

Rate of high risk use low among commercially insured ST. PAUL, Minn., April 1, 2014 /PRNewswire/ -- People who are at high-risk for opioid abuse use had significantly higher total medical costs ($19,513 vs. $5,493) than those who were not at high risk according to a new study by Prime Therapeutics (Prime). The Centers for Medicare & Medicare Services (CMS) defines high risk as "using a daily morphine equivalent dose (MED) of greater than 120 mg for at least 90 consecutive days,...

2014-03-31 23:34:15

Vitamin C and Derivatives Markets in China - a new research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) March 31, 2014 China's demand for vitamin C and derivatives has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major...

2014-03-31 12:23:50

DUBLIN, Mar. 31, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/hx25tb/propanol ) has announced the addition of the "Concise Analysis of the International Propanol (Isopropanol & N-Propanol) Market - Forecasts To 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The global propanol market, including isopropanol and n-propanol, has witnessed a significant growth in the past few years and this growth is...

2014-03-28 08:26:22

NASDAQ: CRME TSX: COM VANCOUVER, March 28, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Cardiome International A.G., a subsidiary of Cardiome Pharma Corp., has entered into an agreement with VIANEX, S.A., headquartered in Erythrea, Greece, for the commercialization and distribution of BRINAVESS(TM) (vernakalant IV) in Greece. Under the terms of the agreement, VIANEX has agreed to specific annual commercial goals for BRINAVESS. "We...

2014-03-28 00:23:11

SAN DIEGO, March 27, 2014 /PRNewswire/ -- We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication. We believe Governor Patrick's ban on Zohydro(TM) ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief...

2014-03-27 08:33:49

Cardiome to conduct conference call and webcast today, March 27, at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CRME TSX: COM VANCOUVER, March 27, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the fourth quarter and year ended December 31, 2013. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States (U.S. GAAP)....

2014-03-27 08:33:37

Ashfield Market Access to provide managed markets and trade support RALEIGH, N.C., March 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. BUNAVAIL is currently under review at the U.S. Food and Drug...

2014-03-26 16:24:39

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3zhmm6/global ) has announced the addition of the "Global Intravenous Solutions Market 2014-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Intravenous Vitamin C therapy has been shown to be effective against a wide variety of cancers. By intravenously injecting Vitamin C into a patient, it was observed that Ascorbate was able to generate a...

2014-03-26 08:28:21

SILVER SPRING, Md., March 26, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin(®) (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost(TM) by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with...

2014-03-26 08:23:34

Management to Detail the Commercialization of High Value Pain Products including Oxycodone using its TPM® Topical Drug Delivery Technology MELBOURNE, Australia, March 26, 2014 /PRNewswire/ --Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY) ("Phosphagenics" or "the Company") announced today that management will host an investor conference call and webcast to discuss the commercial opportunities arising from a range of innovative analgesic products emerging from the Company's...